Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study

Keyphrases

• Atopic Dermatitis 100%
• COVID-19 11%
• COVID-19 Complications 5%
• COVID-19 Incidence 5%
• COVID-19 Infection 5%
• COVID-19 Risk 100%
• COVID-19-associated Hospitalization 17%
• Dupilumab 100%
• Incidence Rate 5%
• Moderate-to-severe Atopic Dermatitis 5%
• Mortality Risk 5%
• Mycophenolate Mofetil 17%
• Non-associated 5%
• Phototherapy 17%
• Population-based Cohort Study 100%
• Safe Drugs 5%
• SARS-CoV-2 Infection 17%
• Systemic Corticosteroids 23%

Pharmacology, Toxicology and Pharmaceutical Science

• Atopic Dermatitis 100%
• Azathioprine 17%
• Cohort Study 100%
• Coronavirinae 5%
• Corticosteroid 23%
• Disease 5%
• Dupilumab 100%
• Infection 23%
• Mycophenolate Mofetil 17%
• SARS Coronavirus 17%